Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.

por Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A., Oglobine, J.
Publicado 1994

Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.

por Bouchet, C., Spyratos, F., Hacène, K., Durcos, L., Bécette, V., Oglobine, J.
Publicado 1998

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.

por Foucré, D., Bouchet, C., Hacène, K., Pourreau-Schneider, N., Gentile, A., Martin, P. M., Desplaces, A., Oglobine, J.
Publicado 1991